Navigation Links
Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
Date:8/15/2012

IRVINE, Calif., Aug. 15, 2012 /PRNewswire/ -- Antigen Discovery Inc. (ADi) today announced that it has received a Phase I Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The two-year $600,000 award will fund a collaborative research effort between ADi and the Henry Samueli School of Engineering at University of California, Irvine (UCI) to develop a fully integrated microfluidic immunodiagnostic platform.  Threats from infectious disease have been growing at an alarming pace worldwide; there is a critical need for accurate, rapid, and readily deployable diagnostics during mass disasters, natural disease outbreaks, and bioterrorist threats.  This joint effort will take advantage of a novel air-liquid cavity acoustic transducer (ALCAT) technology pioneered by Dr. Abraham Lee's group at UCI, and ADi's protein microarray technology and large library of serodiagnostic antigens from dozens of infectious disease targets.  Dr. Xiaowu Liang, President and CEO of ADi, states that "the development of hand-held point-of-care (POC) diagnostics will meet a vital need as the portability, ease-of-use, and prompt sample-to-answer times allow first responders to effectively assess the prevalence and spread of exposure in a population during major outbreaks."  

"We will design and build a microfluidic polymer-based chip that utilizes ALCAT which provides the fluid actuation required for complex reagent handling in multi-step colorimetric immunoassays," added Dr. Abraham Lee, Principle Investigator, Chair of the Department of Biomedical Engineering and Director of the Micro/nano Fluidics Fundamentals Focus (MF3) Center at UCI. "ALCAT's versatility as a single actuation technology is an easier method for on-chip integration compared to other POC platforms that require a different actuator for each fluidic process. By incorporating novel ALCAT-based approaches into protein microarray assays, we will have the versatility and power to reduce enzymatic development times, limit production costs, and fully integrate all components into a disposable assay."

While ADi has received a number of SBIR/STTR awards in the past, this is the first time the company has received a grant for development of a medical device. "Thanks to support from the NIAID, we have been able to build a significant portfolio of diagnostic markers for a wide range of infectious agents," said Dr. Philip Felgner, Founder and Chairman of ADi. "We now plan to develop a point-of-care diagnostic system consisting of a cost-effective disposable microfluidic plastic chip and a portable analyzer that can be driven by a mobile computing device such as a smart phone for rapid serological evaluation of exposure and infections."

About Antigen Discovery Inc.
Antigen Discovery Inc. is a privately owned biotechnology company located in Irvine, California. ADi has a proprietary high throughput proteomics platform technology for biomarker discovery. The company uses and commercializes its innovative proteome microarrays and testing models to facilitate the development of new diagnostic tests, therapeutics and vaccines for infectious disease, autoimmunity, cancer and more. For more information about ADi, see http://www.antigendiscovery.com.

Contact:

Angela Yee
ayee@antigendiscovery.com


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
3. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
4. Generex Augments Antigen Express Scientific Advisory Board
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
7. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
11. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... (PRWEB) , ... August 04, 2020 , ... Fifty six ... to respond more quickly and effectively to a healthcare crisis like COVID-19, according to ... is one of the most important issues for older voters this year,” says Mary ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... , Best Practices During COVID-19, An FDAnews Webinar, Wednesday, Aug. 19, 2020, ... a controlled cleanroom is never simple and COVID-19 has made it more ...
(Date:8/3/2020)... ... August 03, 2020 , ... Seattle’s Infectious ... to amend and restate IDRI’s license with Immune Design, a wholly owned subsidiary ... the amendment, the parties have agreed to modify the licensed fields and indications ...
Breaking Medicine Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... Atlanta Magazine partnered with Castle ... the “Top Doctor” survey. The mission of Castle Connolly Medical Ltd. is to ... and key medical leaders were asked to identify outstanding doctors in their respective ...
(Date:8/5/2020)... ... August 05, 2020 , ... Hypoglycemia (low ... prolonged length of hospital stay, or even death. A researcher at the VA ... Type 2 diabetes to see if the use of continuous glucose monitoring devices ...
(Date:8/5/2020)... ... August 05, 2020 , ... CentrAlert, Inc. today announced the ... to essential COVID-19 information. Know NOW!, which is available for Apple and ... them in one easy-to-use mobile application. , “When COVID-19 first hit, there was so ...
(Date:8/5/2020)... Texas (PRWEB) , ... August 04, 2020 , ... ... older adults living with memory impairment, has announced the Best Memory Care Facilities ... access to experts, facility features and amenities. , According to the ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... the launch of its newest product, CoverageCoach. The site provides a simple and ... purchase insurance products. The company sees CoverageCoach as an important expansion for the ...
Breaking Medicine News(10 mins):